Erste Group Bank Has Pessimistic View of BSX FY2026 Earnings

Boston Scientific Corporation (NYSE:BSX) – Analysts at Erste Group Bank cut their FY2026 earnings estimates for shares of Boston Scientific in a research report issued on Thursday, April 2nd. Erste Group Bank analyst H. Engel now expects that the medical equipment provider will earn $3.45 per share for the year, down from their previous estimate of $3.46. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the firm posted $0.70 EPS. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

Several other equities research analysts have also recently commented on the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. Barclays dropped their price target on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 3rd. TD Cowen reduced their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Mizuho reduced their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.05.

Boston Scientific Stock Performance

Shares of BSX stock opened at $62.69 on Wednesday. Boston Scientific has a one year low of $60.90 and a one year high of $109.50. The company has a market capitalization of $93.17 billion, a price-to-earnings ratio of 32.31, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78. The company’s 50-day moving average is $72.73 and its 200 day moving average is $88.57. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.50% of the stock is currently owned by insiders.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. Vanguard Group Inc. lifted its holdings in Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares in the last quarter. State Street Corp lifted its holdings in Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors lifted its holdings in Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Norges Bank purchased a new stake in Boston Scientific in the 4th quarter worth $2,199,395,000. Finally, Morgan Stanley increased its stake in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after buying an additional 2,246,308 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterated an “Outperform” after the CHAMPION‑AF readout met primary safety and efficacy endpoints, reinforcing the clinical story for BSX’s cardiac franchise and supporting buy‑side interest. Leerink Reiterates Outperform
• Positive Sentiment: Citigroup trimmed its price target (from $94 to $87) but kept a “Buy” rating, signaling continued analyst conviction that shares have upside despite recent share weakness. Citigroup Lowers PT
• Neutral Sentiment: Erste Group marginally cut FY2026 EPS (from $3.46 to $3.45) — a tiny revision that doesn’t materially change the consensus outlook but reflects modest near‑term estimate trimming. Erste Group Lowers Estimate
• Neutral Sentiment: An investor group is probing the proposed acquisition of Penumbra (the deal would pay cash or BSX shares). That scrutiny could slow or complicate deal completion and introduces execution risk if shareholder litigation or regulatory questions arise. Penumbra Sale Probe
• Negative Sentiment: Multiple law firms have filed or circulated investor alerts and class‑action notices accusing BSX and certain officers of securities violations for the period July 23, 2025–Feb 3, 2026; deadlines to seek lead‑plaintiff status are being publicized (notably May 4, 2026). The wave of litigation notices (Bragar Eagel & Squire, Robbins Geller, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Pomerantz, Rosen, Bernstein Liebhard, Gross, etc.) increases litigation risk, potential defense costs and headline volatility. Bragar Alert Robbins Geller Bronstein Faruqi

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.